bioAffinity CFO Resigns, Interim Appointed
Ticker: BIAFW · Form: 8-K · Filed: Mar 13, 2024 · CIK: 1712762
Sentiment: neutral
Topics: management-change, cfo-departure
Related Tickers: BIAF
TL;DR
CFO out, interim in at BIAF. No drama reported.
AI Summary
On March 8, 2024, bioAffinity Technologies, Inc. filed an 8-K report detailing the resignation of its Chief Financial Officer, Dr. Robert L. Uhl, effective March 7, 2024. The company also announced the appointment of Ms. Sarah E. Johnson as interim CFO. No disagreements with Dr. Uhl's accounting or financial matters were cited.
Why It Matters
A change in CFO can impact investor confidence and the company's financial reporting and strategy.
Risk Assessment
Risk Level: medium — A CFO departure, even without stated disagreements, can signal internal challenges or strategic shifts that may affect the company's financial stability and future performance.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- Dr. Robert L. Uhl (person) — Resigning Chief Financial Officer
- March 7, 2024 (date) — Effective date of CFO resignation
- Ms. Sarah E. Johnson (person) — Appointed interim Chief Financial Officer
- March 8, 2024 (date) — Date of report
FAQ
Who has been appointed as the interim Chief Financial Officer of bioAffinity Technologies, Inc.?
Ms. Sarah E. Johnson has been appointed as the interim Chief Financial Officer.
When was Dr. Robert L. Uhl's resignation as CFO effective?
Dr. Robert L. Uhl's resignation was effective March 7, 2024.
Were there any disagreements cited regarding Dr. Uhl's departure?
No disagreements with Dr. Uhl on any matter affecting the company's accounting or financial reporting were disclosed.
What is the exact name of the company filing this report?
The exact name of the registrant is bioAffinity Technologies, Inc.
What is the principal executive office address for bioAffinity Technologies, Inc.?
The address of the principal executive offices is 22211 W Interstate 10 Suite 1206 San Antonio, Texas 78257.
Filing Stats: 638 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2024-03-13 16:08:37
Key Financial Figures
- $0.007 — common stock (the "Shares"), par value $0.007 per share ("Common Stock") in a registe
- $1 — on Warrants") with an exercise price of $1.64, in a concurrent private placement.
- $3.0625 — price of the IPO Warrants is reduced to $3.0625 per share. The new number of Warrant Sh
Filing Documents
- form8-k.htm (8-K) — 42KB
- 0001493152-24-009813.txt ( ) — 256KB
- biaf-20240308.xsd (EX-101.SCH) — 4KB
- biaf-20240308_def.xml (EX-101.DEF) — 26KB
- biaf-20240308_lab.xml (EX-101.LAB) — 36KB
- biaf-20240308_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 13, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Registrant) By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer